This trial is testing a new drug, HMPL-760, on patients who have already been treated for a type of cancer called CLL/SLL or NHL. They're testing how safe and tolerable the drug is, as well as its efficacy.
4 Primary · 7 Secondary · Reporting Duration: From 1st dose of study drug to the time of progressive disease, assessed up to 36 months
168 Total Participants · 3 Treatment Groups
Primary Treatment: HMPL-760 · No Placebo Group · Phase 1
Age 18+ · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: